Last ¥3,045 JPY
Change Today +5.00 / 0.16%
Volume 26.0K
4516 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
As of 8:10 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

nippon shinyaku co ltd (4516) Snapshot

Open
¥3,040
Previous Close
¥3,040
Day High
¥3,045
Day Low
¥3,040
52 Week High
06/24/14 - ¥3,095
52 Week Low
08/8/13 - ¥1,541
Market Cap
213.9B
Average Volume 10 Days
315.7K
EPS TTM
¥85.25
Shares Outstanding
70.3M
EX-Date
09/26/14
P/E TM
35.7x
Dividend
¥25.00
Dividend Yield
0.76%
Current Stock Chart for NIPPON SHINYAKU CO LTD (4516)

Related News

No related news articles were found.

nippon shinyaku co ltd (4516) Related Businessweek News

No Related Businessweek News Found

nippon shinyaku co ltd (4516) Details

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and functional food products in Japan and internationally. The company’s Pharmaceuticals segment offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and others diseases. Its products include Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Cylocide anti metabolic anticancer drug; Cylocide N for relapsed and refractory acute leukemia; Amnolake and Trisenox for relapsed and refractory acute promyelocytic leukemia; and Vidaza for myelodysplastic syndromes. This segment also offers Gaslon N for gastric ulcer and gastritis; Portolac; Azunol gargle liquid, a gargling solution consists of azulene; Livostin for allergy; Baynas for allergic rhinitis; Erizas, a dry powder inhaler for allergic rhinitis; Hypen, a non-steroidal anti-inflammatory and analgesic agent; Tramal for cancer pain; Selectol, a vasodilating beta-1 blocker; Adcirca, a phosphodiesterase-5 inhibitor; Regtect; Lunabell for dysmenorrhea resulting from endometriosis and functional dysmenorrheal; and Cephadol products. The company’s Functional Food segment provides health food ingredients, preservatives, protein preparations, nutritional ingredients, seasonings and spices, sterilization cleaning agents, and other products. Nippon Shinyaku Co. is also involved in the research and development of drugs primarily in urology, hematology, obstetrics and gynecology, otorhinolaryngology, and orthopedics fields of medicine. The company was founded in 1911 and is headquartered in Kyoto, Japan.

1,790 Employees
Last Reported Date: 06/30/14
Founded in 1911

nippon shinyaku co ltd (4516) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nippon shinyaku co ltd (4516) Key Developments

Nippon Shinyaku Co. Ltd. to Report Fiscal Year 2014 Results on May 09, 2014

Nippon Shinyaku Co. Ltd. announced that they will report fiscal year 2014 results on May 09, 2014

Nippon Shinyaku Co. Ltd. Reports Consolidated Earnings Results for the Year Ended March 31, 2014; Provides Earnings Guidance for the Half Year of Fiscal Year 2015 and Year Ending March 31, 2015

Nippon Shinyaku Co. Ltd. reported consolidated earnings results for the year ended March 31, 2014. For the year, the company reported net sales of ¥76,517 million against ¥69,941 million a year ago. Operating income was ¥8,038 million against ¥6,901 million a year ago. Ordinary income was ¥8,598 million against ¥7,209 million a year ago. Income before minority interests was ¥5,760 million against ¥4,660 million a year ago. Net income was ¥5,750 million or ¥85.25 per basic share compared ¥4,647 million or ¥68.87 per basic share reported a year ago. Net cash provided by operating activities were ¥6,015 million against ¥3,767 million a year ago. Purchases of tangible fixed assets were ¥1,121 million against ¥1,020 million reported a year ago. Purchases of intangible assets were ¥142 million against ¥359 million reported a year ago. For the half year of fiscal ending March 31, 2015, the company expects to report net sales of ¥38,300 million, operating income of ¥2,000 million, ordinary income of ¥2,100 million and net income of ¥1,400 million or ¥20.76 per basic share. For the year ending March 31, 2015, the company expects to report net sales of ¥84,000 million, operating income of ¥8,500 million, ordinary income of ¥8,700 million and net income of ¥6,000 million or ¥88.98 per basic share.

Nippon Shinyaku Co. Ltd., Annual General Meeting, Jun 27, 2014

Nippon Shinyaku Co. Ltd., Annual General Meeting, Jun 27, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4516:JP ¥3,045.00 JPY +5.00

4516 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.109.30 CHF -1.50
United Therapeutics Corp $90.85 USD -0.74
View Industry Companies
 

Industry Analysis

4516

Industry Average

Valuation 4516 Industry Range
Price/Earnings 36.1x
Price/Sales 2.7x
Price/Book 2.2x
Price/Cash Flow 35.4x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NIPPON SHINYAKU CO LTD, please visit www.nippon-shinyaku.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.